← All trials
NCT06598072
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 19, 2024
- Last posted
- Sep 20, 2024
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Colgate PalmoliveLead sponsor
- Universidad Autonoma de San Luis PotosiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.